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(57) ABSTRACT 
A group I intron-derived ribozyme Which binds RNA in trans, 
excises an internal segment from Within the RNA, and splices 
the remaining 5' and 3' ends of the RNA back together (the 
trans-excision-splicing reaction) is disclosed. The excised 
segment can be as long as 28 nucleotides, or more, and as little 
as one nucleotide. The ribozymes of the invention are easily 
modi?ed to alter their sequence speci?city. Such ribozymes 
represent a neW and potentially powerful class of generally 
adaptable genetic therapeutics. 
10 Claims, 8 Drawing Sheets 
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TRANS-EXCISION-SPLICING RIBOZYME 
AND METHODS OF USE 
RELATED APPLICATIONS 
This application is a divisional ofU.S. Ser. No. 10/730,261, 
?led on Dec. 9, 2003 now US. Pat. No. 7,211,661, Which in 
turn claims the bene?t of US. Provisional Application No. 
60/431,965, ?led on Dec. 10, 2002, the disclosures of Which 
Applications are incorporated by reference herein. 
FIELD OF THE INVENTION 
This invention relates generally to the ?eld of genetic 
therapeutics. More particularly, the invention relates to a 
trans-excision-splicing riboZyme having adaptable sequence 
recognition speci?city that provides a powerful tool for 
genetic therapies. 
BACKGROUND OF THE INVENTION 
The discovery of catalytic RNA fundamentally changed 
the course of science. The subsequent realiZation that cata 
lytic RNAs could be tailored to suit individual needs has been 
nothing less than inspiring. Indeed, the past ten years has seen 
the creative development of numerous RNA catalysts. Con 
currently, the diversity of applications for these catalytic 
RNAs has been escalating. For example, catalytic RNAs are 
being developed for detection protocols, for therapeutic inter 
vention of diseases, and for use as biochemical tools. As We 
continue to exploit the steadily increasing knowledge base of 
RNA structure, folding, and catalysis, designing and applying 
novel and effective RNA catalysts is becoming more and 
more tractable. 
RiboZymes are RNA molecules having an enZymatic activ 
ity, Which enables the riboZyme to repeatedly cleave other 
separate RNA molecules in a nucleotide base sequence-spe 
ci?c manner. Such enZymatic RNA molecules can be targeted 
to virtually any RNA transcript, and e?icient cleavage 
achieved in vitro. Kim et al., 84 Proc. Natl. Acad. Sci. USA 
8788, 1987; Haseloff and Gerlach, 334 Nature 585, 1988; 
Cech, 260 JAMA 3030, 1988; and Jefferies et al., 17 Nucleic 
Acids Research 1371, 1989. 
RiboZymes act by ?rst binding to a target RNA. Such 
binding occurs through the target RNA binding portion of a 
riboZyme, Which is held in close proximity to an enZymatic 
portion of the RNA that acts to cleave the target RNA. Thus, 
the riboZyme ?rst recogniZes and then binds a target RNA 
through complementary base-pairing, and once bound to the 
correct site, acts enZymatically to cut the target RNA. Strate 
gic cleavage of such a target RNA destroys its ability to direct 
synthesis of an encoded protein. After a riboZyme has bound 
and cleaved its RNA target it is released from that RNA to 
search for another target and can repeatedly bind and cleave 
neW targets. 
Six basic varieties of naturally-occurring enZymatic RNAs 
are knoWn presently. Each can catalyZe the hydrolysis of 
RNA phosphodiester bonds in trans (and thus can cleave other 
RNA molecules) under physiological conditions. In general, 
enZymatic nucleic acids act by ?rst binding to a target RNA. 
Such binding occurs through the target binding portion of an 
enZymatic nucleic acid Which is held in close proximity to an 
enZymatic portion of the molecule that acts to cleave the 
target RNA. Thus, the enZymatic nucleic acid ?rst recogniZes 
and then binds a target RNA through complementary base 
pairing, and once bound to the correct site, acts enZymatically 
to cut the target RNA. Strategic cleavage of such a target RNA 
Will destroy its ability to direct synthesis of an encoded pro 
tein. After an enZymatic nucleic acid has bound and cleaved 
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its RNA target, it is released from that RNA to search for 
another target and can repeatedly bind and cleave neW targets. 
A catalytic RNA that can excise a speci?c RNA sequence 
out of a larger RNA (the trans-excision-splicing reaction), 
although not previously discovered or engineered, Would be 
very useful as a biochemical tool and also as a potential neW 
therapeutic strategy. For example, multiple turnover catalytic 
RNAs, or riboZymes, With this activity couldbe used to excise 
a disease-causing RNA region out of a native transcript, to 
remove a premature stop codon, or to restore a frameshift 
mutation, for example. 
SUMMARY OF THE INVENTION 
In one aspect of the invention there is provided a trans 
excision-splicing riboZyme comprising at least tWo recogni 
tion elements that are complementary to a target sequence 
Within a substrate, Wherein the target sequence is not comple 
mentary to native recognition elements, Wherein at least one 
of said recognition elements stabiliZes binding of the 
riboZyme to a trans-excision splicing (TES) reaction interme 
diate product, and Wherein the riboZyme catalyZes a speci?c 
excision of the target sequence and splices the 5' end of the 
substrate created by the excision to an 00G of the 3' end of the 
substrate created by the excision. 
In another aspect of the invention there is provided a poly 
nucleotide molecule comprising a riboZyme expression cas 
sette that is capable of being stably inserted into a host, the 
cassette comprising a promoter operably-linked to a nucle 
otide sequence encoding a trans-excision-splicing riboZyme 
comprising at least tWo recognition elements that are comple 
mentary to target sequence Within a substrate other than that 
complementary to native recognition elements, Wherein at 
least one of said recognition elements stabiliZes binding of 
the riboZyme to a trans-excision splicing (TES) reaction inter 
mediate product and Wherein the riboZyme catalyZes a spe 
ci?c excision of the target sequence and splices the 5' end of 
the substrate created by the excision to an 00G of the 3' end of 
the substrate created by the excision. 
Also provided are host cells transfected With the poly 
nucleotide molecule. 
In yet another aspect of the invention there is provided a 
method for in vitro trans-splicing-excison of a target 
sequence, comprising the steps of: 
(1) providing the riboZyme of the invention in a trans 
splicing reaction mixture; 
(2) providing a substrate comprising the target sequence to 
the reaction mixture; and 
(3) catalyZing the trans-splicing-excision of the target 
sequence. 
In another aspect of the invention there is provided a 
method for deleting an undesired genetic sequence from a 
host cell in vivo, said method comprising: 
(1) providing the riboZyme of the invention to the host cell, 
said riboZyme possessing catalytic activity against a target 
RNA sequence present in said host cell, 
Wherein the riboZyme catalyZes a speci?c excision of the 
target RNA sequence and splices the 5' end of the substrate 
created by the excision to an 00G of the 3' end of the substrate 
created by the excision. 
The folloWing de?nitions are used herein. 
RiboZyme: An RNA molecule that inherently possesses cata 
lytic activity. 
Trans-splice: A form of genetic manipulation Whereby a 
nucleic acid sequence of a ?rst polynucleotide is colinearly 
linked to or inserted colinearly into the sequence of a second 
polynucleotide, in a manner that retains the 3'-5' phosphodi 
ester linkage betWeen such polynucleotides. By “directed” 
US 7,776,835 B2 
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trans-splicing or “substrate-speci?c” trans-splicing is meant a 
trans-splicing reaction that requires a speci?c specie of RNA 
as a substrate for the trans-splicing reaction (that is, a speci?c 
specie of RNA in Which to splice the transposed sequence). 
Directed trans-splicing may target more than one RNA specie 
if the riboZyme is designed to be directed against a target 
sequence present in a related set of RNAs. 
Target sequence: A nucleic acid molecule, e.g., RNA, that is 
a substrate for the catalytic activity of a riboZyme of the 
invention. 
Expression Cassette: A genetic sequence that provides 
sequences necessary for the expression of a riboZyme of the 
invention. 
Stably: By “stably” inserting a sequence into a genome is 
intended insertion in a manner that results in inheritance of 
such sequence in copies of such genome. 
Operable linkage: An “operable linkage” is a linkage in Which 
a sequence is connected to another sequence (or sequences) in 
such a Way as to be capable of altering the functioning of the 
sequence (or sequences). For example, by operably linking a 
riboZyme encoding sequence to a promoter, expression of the 
riboZyme encoding sequence is placed under the in?uence or 
control of that promoter. TWo nucleic acid sequences, such as 
a riboZyme encoding sequence and a promoter region 
sequence at the 5' end of the encoding sequence, are said to be 
operably linked if induction of promoter function results in 
the transcription of the riboZyme encoding sequence and if 
the nature of the linkage betWeen the tWo sequences does not 
(1) result in the introduction of a frame-shift mutation, (2) 
interfere With the ability of the expression regulatory 
sequences to direct the expression of the riboZyme. Thus, a 
promoter region Would be operably linked to a nucleic acid 
sequence if the promoter Were capable of effecting the syn 
thesis of that nucleic acid sequence. 
Native target sequence/Non-native target sequence: Native 
target sequence of a riboZyme is that polynucleotide sequence 
Which is recogniZed, bound and reacted by Wild-type (native) 
riboZymes. Non-native target sequence is sequence Within a 
substrate that is not bound by Wild type riboZyme and conse 
quently native riboZyme does not react With non-native target 
sequence. Non-native target sequence can occur as a result of 
mutation, for example. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1. The Group I Intron Self-Splicing (111: left) and 
Trans-Excision-Splicing Reactions (1b: right). The catalytic 
RNAs are represented by gray lines, the 5' and 3' exons and 
mimics are black lines, and the bridge (excised region) is a 
dotted line. The circle in the 5' exon represents a uridine and 
the circle in the 3' exon represents a guanosine. The intron 
inherently contains all the required activities for the trans 
excision-splicing reaction. REl, RE2, and RE3 are three rec 
ognition elements that the catalytic RNAs may use to base 
pair With their substrates (RE3 is also referred to as the IGS, 
or Internal Guide Sequence.). It is likely that RE2 and/ or RE3 
do not bind the substrate until after the ?rst reaction step. In 
addition, at least With the rP-8/4x riboZyme used herein, the 
guanosine cofactor is not required for initiation of the ?rst 
catalytic step. 
FIG. 2. The rP-8/4x and rP-8/4x-MD RiboZymes Base 
Pairing With Various Substrates. 2A) The R carinii riboZyme, 
rP-8/4x (uppercase lettering, SEQ ID NO:9), binding to the 
36-mer substrate (loWercase lettering With a gray back 
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ground, SEQ ID NO: 1 0). In the trans-excision-splicing reac 
tion, the bridging region (White lettering) is excised and the 5' 
and 3' regions of the substrate (black lettering) are subse 
quently spliced together. Note that PI, P9.0, and P10 are 
helices that result from the recognition elements REl, RE2, 
and RE3 base pairing With the substrate. The large bold 
arroWs indicate the sites of catalysis for the ?rst (left) and 
second (right) step of the trans-excision-splicing reaction. 
The 5' uridine and 3' guanosine are circled. The riboZyme 
bases are numbered according to that for the R carinii intron 
(Testa, S. M., Haidaris, C. G., Gigliotti, E, & Turner, D. H. 
(1997) Biochemistry 36, l5303-l53l4.l3, incorporated 
herein in its entirety). 2B). Simpli?ed diagrams of various 
substrates base pairing With various riboZymes. Only the 
recognition element sequences are shoWn for the riboZymes. 
The dashed line indicates a normal phosphodiester bond 
betWeen the adjoining sequences. i) The l2-mer substrate 
(SEQ ID NO:7) binding to rP-8/4x (SEQ ID NO: 1 1). ii) The 
l0-mer substrate (SEQ ID NO:8) binding to rP-8/ 4x (SEQ ID 
NO:1 1). iii) The 38-mer Myotonic Dystrophy substrate (SEQ 
ID NO:l2) binding to the rP8/4x-MD Myotonic Dystrophy 
riboZyme (SEQ ID NO:l3). 
FIG. 3. The Trans-Excision-Splicing Reaction using the R 
carinii system. The Trans-Excision-Splicing (TES) Reaction 
Using the R carinii System. A) Polyacrylamide gel shoWing 
substrates and products of the TES reaction using 166 nM 
rP-8/4x riboZyme and 1.33 nM substrate at 7 mM MgCl2 
(36-mer) and 10 mM MgCl2 (l0-mer and l2-mer) at 440 C. 
The reaction using the 36-mer substrate is diagrammed on the 
left (SEQ ID NO:10, SEQ ID NO:14, and SEQ ID NO:15). 
The regions of the substrate that bind to the riboZyme’s rec 
ognition elements (labeled REl (SEQ ID NO: 15), RE2, and 
RE3) are underlined. All reactions in the presence (+) and 
absence (—) of the rP-8/4x riboZyme Were subjected to the 
same incubation conditions. TES reactions Were conducted 
using a 36-mer substrate (to give a l6-mer product), a l2-mer 
substrate (9-mer product), and a l0-mer substrate (9-mer 
product). See FIG. 2 for the sequence of these substrates. The 
6-mer lane shoWs a synthetic control for the 5' cleavage prod 
ucts, the l6-mer lane shoWs a synthetic control for the l6-mer 
TES product, and the ‘OH lane shoWs an alkaline digest of 
the 36-mer starting material. B). Graphs of TES reactions 
using the 36-mer substrate. All reactions Were run as above 
except for the changing variable. The TES product is repre 
sented by ?lled circles and the 5' cleavage product by open 
circles. C). Graphs of TES reactions using the l0-mer sub 
strate. All reactions Were run as above except for the changing 
variable. The TES product is represented by ?lled triangles 
and the 5' cleavage product by open triangles. Each graph 
shoWs the average of tWo independent assays. 
FIG. 4. Sequencing of Trans-Excision-Splicing Products. 
For each system, a chemically synthesiZed version of the 
expected product Was sequenced and run adjacent to the 
isolated excision product. Left: the R carinii l6-mer product 
that results from treating the 36-mer substrate With the rP-8/ 
4x riboZyme. Right: the Myotonic Dystrophy l0-mer product 
that results from treating the 38-mer substrate With the rP-8/ 
4x-MD riboZyme. The dotted line represents the neWly cre 
ated splice junctionbetWeen the 5' and 3' ends of the substrate. 
Nuclease T1 is speci?c for guanosine, U2 for adenosine, and 
CL-3 primarily for cytidine. The ‘OH lane shoWs an alkaline 
digest of the starting material, and the lanes labeled ‘Start’ 
shoW the starting material. 
FIG. 5. Competition TES Reactions. Polyacrylamide gel 
shoWing substrates and products of TES reactions using 166 
nM rP-8/4x, 7 mM MgCl2, and 440 C. ‘Radiolabeled sub 
strate’ refers to the length of the radiolabeled substrate at 1.33 
US 7,776,835 B2 
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nM ?nal concentration and ‘cold substrate’ refers to the 
length of the non-radiolabeled substrate. The ?nal concentra 
tions of the cold substrates are 1.33 nM for the 36-mer, and 
66.5 nM (50><) or 665 nM (500><) for the 7-mer, Which is 
r(GUGCUCU) (SEQ ID NO: 16). The tWo substrates for each 
reaction Were added simultaneously. Lanes designated in the 
?rst box are length controls, the second box shoWs the 5' exon 
competition assay, the third box shoWs an alkaline digest of 
the 36-mer starting material, and the fourth box shoWs the 3' 
exon competition assay. 
FIG. 6. The TES Reaction Using the DMPK Model Sys 
tem. A) Polyacrylamide gel shoWing substrates and products 
of the TES reaction using 166 nM rP-8/4x-MD riboZyme, 
1.33 nM substrate, 13 mM MgCl2, and 440 C. The reaction 
using the 38-mer DMPK mimic is diagrammed on the left 
(SEQ ID NO:12, SEQ ID NO:17 and SEQ ID NO:18). The 
regions of the substrate that bind to the riboZyme’s recogni 
tion elements are labeled RE1 (SEQ ID NO:18), RE2, and 
RE3. All reactions in the presence (+) and absence (—) of the 
rP-8/4x-MD riboZyme Were subjected to the same incubation 
conditions. TES reactions Were conducted using the 38-mer 
substrate (to give a 10-mer product). The 6-mer lane shoWs a 
synthetic control for the 5' cleavage products, the 10-mer lane 
shoWs a synthetic control for the 10-mer TES product, and the 
iOH lane shoWs an alkaline digest of the 38-mer starting 
material. The lanes labeled 36 are TES reactions using the 
rP-8/4x-MD riboZyme With the 36-merR carinii substrate (at 
13 mM MgCl2), and the lane labeled 38 (lane 0) is a reaction 
using the rP-8/ 4x riboZyme With the 3 8-mer DMPK mimic (at 
7 mM MgCl2). In these cases, no reaction occurs. B). Graphs 
of TES reactions using the 38-mer substrate and rP-8/4x-MD. 
All reactions Were run as above except for the changing 
variable. The TES product is represented by ?lled squares and 
the 5' cleavage product by open squares. 
FIG. 7. TES reactions using tWo different Telrahymena 
riboZymes. FIG. 7A is a polyacrylamide gel shoWing sub 
strates, intermediates, and products of the TES reaction. The 
reaction Was carried out for 90 minutes using 166 nM 
riboZyme and 1 .33 nM radiolabeled 13 -mer substrate at either 
0 mM or 10 mM MgCl2 at 44 degrees C., either in the presence 
(+) or absence (—) of330 nM GMP. FIG. B is a diagram ofthe 
TES reaction (SEQ ID NO:19 and SEQ ID NO:20). The 
excised G of SEQ ID NO:19 is in bold lettering. FIG. 7C 
shoWs tWo graphs of TES reactions using the 13-mer sub 
strate and the A-L-21 Sca riboZyme (Telrahymena). The TES 
product is represented by the ?lled circles and the 5' interme 
diate (CUCUCU) (SEQ ID NO:21) is represented by open 
circles. All reactions Were run as above except for the chang 
ing variable. Each curve represents the average of tWo inde 
pendent assays. Standard deviation for all points Was less than 
10%. For clarity the graphs use different scales. 
DETAILED DESCRIPTION OF THE INVENTION 
The inherent binding and catalytic activity of group I 
intron-derived riboZymes can be exploited to catalyZe the 
trans-excision-splicing reaction. FIG. 1a shoWs a simple dia 
gram of a typical group I intron-catalyZed self-splicing reac 
tion. There are three base pairing contacts that the intron uses 
to hold and position its 5' and 3' exons for subsequent cataly 
sis. We have termed these the riboZyme recognition elements, 
or RE1 , RE2, and RE3. Physically removing the intramolecu 
lar exons from the intron creates a riboZyme that has the 
ability to bind and catalyZe reactions using exogenous sub 
strates that contain 5' and 3' exon sequences (Zaug, A. J. & 
Cech, T. R. (1986) Science 231, 470-475.). If the 5' and 3' 
exon sequences are connected With a bridging sequence and 
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recognition elements are maintained, this riboZyme can 
excise the bridging sequence and splice the 5' and 3' ends of 
the substrate together. A simple diagram of this trans-exci 
sion-splicing reaction is shoWn in FIG. 1b. This reaction Was 
tested using a riboZyme, rP-8/4x, from the opportunistic 
pathogen Pneumocyslis carinii. In FIG. 2A it is shoWn that 
this riboZyme catalyZes the trans-excision-splicing reaction 
using a synthetic substrate Which is complementary to the 
native recognition elements of the rP-8/4x riboZyme. More 
over, as little as a single nucleotide can be excised. 
In order for this reaction to be useful, hoWever, the 
riboZyme recognition elements have to be mutable, such that 
the riboZyme can be targeted to bind With and react on non 
native sequences. Using a group I intron-derived riboZyme 
from Telrahymena lhermophila, the sequence of RE1 (also 
referred to as the IGS, or Internal Guide Sequence) Was 
mutated and the resultant riboZyme then bound to a neW, 
complementary substrate (Murphy, F. L. & Cech, T. R. (1989) 
Proc. Natl. Acad. Sci. USA. 86, 9218-9222; Been, M. D. & 
Cech, T. R. (1 986) Cell 47, 207-216; Zaug,A. 1., Been, M. D., 
& Cech, T. R. (1986)Nalure 324, 429-433). This property has 
been exploited for, among other purposes, designing trans 
splicing riboZymes that can replace the 3' end of mutant 
transcripts With corrected versions (Sullenger, B. A. & Cech, 
T. R. (1994) Nature 371, 619-6; Lan, N., HoWrey, R. R, Lee, 
S. W., Smith, C. A., & Sullenger, B. A. (1998) Science 280, 
1 593 -1 5 96). 
Trans-excision-splicing riboZymes are ideal for treating 
genetic diseases for Which the causative affects may be ame 
liorated by the excision of an internal RNA segment out of a 
larger RNA, including triplet-expansion diseases such as 
Huntington’s disease, Fragile X, and Myotonic Dystrophy 
(BoWater, R. P. & Wells, R. D. (2001) Prog. Nucleic Acid Res. 
Mol. Biol. 66, 159-202). Patients affected With these diseases 
have an RNA that is present in normal individuals, except that 
embedded Within it is an abnormally high number of tandem 
repeat sequences. For Myotonic Dystrophy, the expansion is 
in the 3' UnTranslated Region [3' UTR] of a serine-threonine 
protein kinase gene [the DMPK gene], Whose expression 
induces the expression of skeletal muscle speci?c genes. The 
disease state of Myotonic Dystrophy, Which is the most com 
mon form of adult onset Muscular Dystrophy, typically has 
much more than 35 CUG repeats, While unaffected individu 
als typically have less than 15 repeats. The greater the number 
of repeats, the more severe the affects of the disease. More 
over, strong experimental evidence indicates the disease 
stems directly from the RNA repeats, and not to any affected 
coding potential of the parent DNA. In fact, the Myotonic 
Dystrophy triplet-expansion and recently discovered quadru 
plet-expansion diseases have the repeat sequences Within 
non-coding regions, so their effects are not due to the synthe 
sis of mutant proteins. A neW class of riboZymes that can 
speci?cally excise these expanded RNA repeats from the 
transcripts could aid in the development of much needed 
therapeutics against these types of diseases. 
The rP-8/4x riboZyme Was re-engineered to test the poten 
tial to alter the sequence speci?city of trans-excision-splicing 
riboZymes to bind and excise the triplet expansion region 
from a Myotonic Dystrophy DMPK small model system in 
vitro. The resultant riboZyme excises the triplet expansion 
region, and in a sequence speci?c manner. That trans-exci 
sion-splicing riboZymes can be re-engineered to target and 
act upon predetermined sequences demonstrates a general 
usefulness for these riboZymes as biochemical tools and 
therapeutics. 
R carinii Group I Intron RiboZyme CatalyZes the Trans 
Excision-Splicing Reaction. 
A riboZyme derived from a P carinii group I intron cata 
lyZes a previously unreported excision-splicing reaction on 
an exogenous substrate. This trans-excision-splicing reaction 
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takes advantage of the catalytic abilities of this riboZyme. 
First, rapid and e?icient sequence-speci?c cleavage of a des 
ignated substrate occurs in a guanosine independent fashion, 
as previously reported (Testa, S. M., Haidaris, C. G., Gigliotti, 
F., & Turner, D. H. (1997) Biochemistry 36, 15303-15314.). 
Second, the resultant 5' cleavage product can splice to a 
sequence that binds the 3' end of the riboZyme (Inoue, T., 
Sullivan, F. X., & Cech, T. R. (1985) Cell 43, 431-437) (FIG. 
1B). These activities Were exploited by designing a synthetic 
substrate that contains Within it the sequences required for 
each catalytic event, separated by an internal bridging 
sequence (FIG. 2A). As seen in FIG. 3, the engineered 
riboZyme catalyZes the speci?c excision of the bridge 
sequence and splices the 5' and 3' ends of the substrate back 
together. Even though there are 1 8 other uridines that could be 
sites of 5' cleavage and 4 other guanines that could be sites of 
3' splicing, only one trans-excision-splicing product is gen 
erated. Apparently, the riboZyme recognition elements that 
de?ne the individual catalytic steps are sequence speci?c. 
That the riboZyme can catalyZe this reaction is surprising in 
that the relatively long bridging region could be expected to 
sterically hinder the binding of the substrate to the catalytic 
core of the riboZyme or hinder the required conformational 
rearrangement betWeen the tWo catalytic steps (Cech, T. R., 
Herschlag, D., Piccirilli, J. A., & Pyle, A. M. (1992) J. Biol. 
Chem. 267, 17479-17482; and 39. Jaeger, L., Michel, F. & 
Westhof, E. (1996) in Catalytic RNA, eds. Eckstein, F. & 
Lilley, D. (Heidelberg, Germany), Vol. 10, pp. 1-17). Perhaps 
this accounts for over 50% of the substrate only undergoing 
the ?rst catalytic step (see FIG. 3). In addition, like other 
riboZymes, the R carinii riboZyme binds its 5' exon sequences 
orders of magnitude tighter than its 3' exon sequences, Which 
alloWs time for 3' end dissociation prior to the second cata 
lytic step. Nevertheless, a signi?cant amount of trans-exci 
sion-splicing product is generated. Another consideration is 
that the 5' exon of one substrate could ligate to the 3' exon of 
another substrate. Since spontaneous 3' splice site hydrolysis 
is essentially non-existent and only an insigni?cant amount of 
5' exon-bridge 26-mer product (Which Would be a side reac 
tion of this catalytic event) is produced, it is unlikely that this 
mechanism occurs to a signi?cant extent. 
The R carinii riboZyme can excise as little as one nucle 
otide. The P carinii riboZyme excises as little as a single 
nucleotide, and in a sequence-speci?c manner. Apparently, 
there is no loWer limit to the siZe of the region being excised. 
That the same approximate yield is obtained regardless of 
Whether the 12-mer (39%) and 10-mer (36%) substrate is 
used suggests that the role of forming the P90 helix is not 
large in this case, as the 10-mer lacks the ability to form the 
P90 helix. Therefore, the RE2 interaction, although perhaps 
bene?cial, is not required to establish a sequence speci?c 
interaction. In addition, the 12-mer and 10-mer substrates 
lead to approximately 50% more product as compared With 
the 36-mer substrate. There are many possible explanations 
for this, including the longer bridge of the 36-mer substrate 
partially interfering With the substrate’s ability to bind the 
recognition elements. 
The sequence speci?city of the P carinii riboZyme can be 
altered. Altering the recognition elements of the R carinii 
riboZyme changes the sequence speci?city of the trans-exci 
sion-splicing reaction. While it Was knoWn that RE1 could be 
modi?ed in reactions mimicking the ?rst step of the self 
splicing reaction, it Was previously not knoWn that all three 
elements are mutable. That these recognition elements com 
pletely specify binding and reactivity indicates that they are 
the primary determinants of speci?city betWeen the riboZyme 
and its substrate. In addition, bridging regions of different 
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sequences and lengths (1, 3, 20, and 28 nucleotides) have 
been excised, indicating that the 3' G in the bridging region 
might be the only potential sequence requirement for the 
excised segment. Structure might even be tolerated Within the 
excised region, as the someWhat structured CUG repeat 
Within the Myotonic Dystrophy substrate doesn’t prohibit the 
reaction. In addition, each riboZyme only acts upon its des 
ignated target, even though the RBIs in both riboZymes are 
50% identical, giving a further indication of the high level of 
sequence speci?city of this reaction. Although the MgCl2 
concentration required for maximum activity is different for 
the tWo riboZymes (7 and 13 mM), they both are active 
throughout the same general MgCl2 concentration range 
(data not shoWn), Which is beloW that required (15 mM) for 
maximum activity for the R carinii group I intron self-splic 
ing reaction in vitro. 
The ability to catalyZe TES reactions is inherent to Group 
I introns. To determine Whether other riboZymes can catalyZe 
TES reaction, a TeZrahymena-containing L-21 ScaI plasmid 
Was lineariZed With ScaI, run-off transcriptions Were per 
formed, and the riboZyme Was puri?ed as described by Testa 
et al. (Biochemistry, (1997) 36:15303-15314). TES reactions 
Were run in a variety of standard buffers and conditions rou 
tinely used for riboZyme reactions. The reactions Were also 
run in the presence and absence of the PG cofactor. In all 
cases, the ?rst step of the reaction Was the only reaction step 
that Was detected. 
The lack of a full-length, second-step reaction product 
suggests that the second step may be inef?cient or problem 
atic With this riboZyme. Our previous studies of the R carinii 
riboZyme had demonstrated that 3' intermediate disassocia 
tion results in signi?cantly reduced second-step yields. 
Therefore, the Telrahymena riboZyme Was modi?ed to con 
tain an RE3 region in order to stabiliZe binding of the 
riboZyme to the ’3 exon reaction intermediate. The results are 
shoWn in FIG. 6. The reaction using the stabiliZed riboZyme 
generates a product band of the expected siZe (a 12-mer 
product from a 13-mer substrate). The product band Was 
excised from the band and sequenced, and shoWn to be the 
expected TES product. These results demonstrate that the 
ability to catalyZe TES reactions is a general property inher 
ent to group I introns. 
Comparison With the Trans-Splicing Reaction. The trans 
excision-splicing reaction of the invention is fundamentally 
different from the trans-splicing reaction previously reported 
(Sullenger, B. A. & Cech, T. R. (1994) Nature 371, 619-622.), 
Whereby a riboZyme covalently attached to a normal RNA 
sequence binds to a mutant RNA transcript, cleaves the 
mutant transcript, and replaces the 3' end of the mutant tran 
script With the normal ‘corrected’ version. While trans-splic 
ing can correct mutant RNA, it is single-turnover, it exploits 
only the RBI molecular interaction, and the riboZyme must be 
covalently attached to the neW, corrected transcript. In con 
trast, the trans-excision-splicing reaction is potentially mul 
tiple turnover; it exploits the RBI, RE2, and/or RE3 molecu 
lar interactions; and it excises an internal segment from 
Within a larger RNA. Nevertheless, these tWo complementary 
reactions share many similarities and so the Wealth of knoWl 
edge already reported for the trans-splicing reaction is appli 
cable to the trans-excision-splicing reaction. 
Implications for Myotonic Dystrophy. The rP-8/4x 
riboZyme can be redesigned to speci?cally excise the entire 
triplet expansion region of a mimic of the Myotonic Dystro 
phy transcript, implicating such riboZymes as neW types of 
potential Muscular Dystrophy therapeutics. As a practical 
matter, cutting out this entire region may or may not restore 
proper function to the transcript, as normal individuals typi 
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cally have at least 5 repeats. Similar multiple turnover 
riboZymes, however, can be designed to target the repeats 
themselves to successively reduce expansion lengths. 
General Therapeutic Implications. Unfortunately, nature 
has afforded a huge number ofRNA-mediated mutations that 
predispose individuals to disease. NeW therapeutic strategies 
to combat these diseases are needed. That the recognition 
elements of the rP-8/ 4x riboZyme canbe modi?ed and the siZe 
and sequence of the excised region do not appear to have 
limitations suggest that trans-excision-splicing riboZymes 
may be generally useful as therapeutics against many such 
diseases. For example, excising speci?c sequences could 
remove premature stop codons, restore altered reading 
frames, or remove insertion mutations that affect transcrip 
tion and translation regulation. 
Trans-excision-splicing riboZymes are thought to have tWo 
sequence preferences. The ?rst is a uridine at the 5' cleavage 
site (although a cytidine might also Work) and the second is a 
guanosine at the 3' splice site (FIG. 2A). Therefore, there are 
three simple targeting strategies to consider. First, a riboZyme 
can be designed that targets a uridine 5' to any particular 
mutation and a guanosine 3' to this mutation, as is the case in 
the Myotonic Dystrophy model system described here. It 
should be noted that if more than an insertion mutation is 
excised the neW transcript might not function normally. Sec 
ond, a mutation that results in a neW guanosine canbe targeted 
as the 3' splice site. The above strategies Will also target 
normal transcripts for at least the ?rst step of the reaction, so 
these strategies should be designed With care. Third, a muta 
tion that results in a neW uridine can be targeted as the 5' 
cleavage site. This resultant riboZyme Would not attack the 
normal transcript, but Would perform both steps on the mutant 
transcript. Since point mutations that result in premature ter 
mination codons often involve a neW uridine (all termination 
codons begin With uridine), hundreds of distinct mutations 
could be speci?cally targeted. Therefore, many options for 
targeting are possible, Which expands the potential usefulness 
of these riboZymes. The general strategy of targeting muta 
tions at the RNA level, hoWever, should be considered a 
potential treatment rather than a potential cure, as mutant 
RNA transcripts Will continue to be produced. 
As shoWn herein, group I intron-derived riboZymes 
obtained from different organisms can catalyZe this neW 
trans-excision-splicing reaction. In addition, the sequence of 
the riboZyme can be easily manipulated such that it targets 
and acts upon desired substrates, including those of medical 
importance. The reactions themselves appear highly 
sequence speci?c and as little as a single nucleotide can be 
excised. The applicability of trans-excision-splicing 
riboZymes to treat disease has been demonstrated by design 
ing a riboZyme that speci?cally removes the triplet expansion 
region that is involved in a common form of Muscular Dys 
trophy in a small model system in vitro. Therefore, trans 
excision-splicing riboZymes are a neW class of riboZymes that 
permits potential biochemical and therapeutic strategies not 
before possible. 
The riboZymes of the invention can be introduced into and 
expressed in a host cell. Transcription of the riboZyme of the 
invention in a host cell occurs after introduction of the 
riboZyme gene into the host cell. If the stable retention of the 
riboZyme by the host cell is not desired, the riboZyme may be 
chemically or enZymatically synthesiZed and provided to the 
host cell by mechanical methods, such as microinjection, 
liposome-mediated transfection, electroporation, calcium 
phosphate precipitation, or the like. Alternatively, When 
stable retention of the gene encoding the riboZyme is desired, 
such retention may be achieved by stably inserting at least one 
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DNA copy of the riboZyme into the host’s chromosome, or by 
providing a DNA copy of the riboZyme on a plasmid that is 
stably retained by the host cell. Preferably the riboZyme of the 
invention is inserted into the host’s chromosome as part of an 
expression cassette, Which provides transcriptional regula 
tory elements that control the transcription of the riboZyme in 
the host cell. Such elements may include, but not necessarily 
be limited to, a promoter element, an enhancer or UAS ele 
ment, and a transcriptional terminator signal. Polyadenyla 
tion is not necessary as the riboZyme is not translated. 
Expression of a riboZyme Whose coding sequence has been 
stably inserted into a host’s chromosome is controlled by the 
promoter sequence that is operably linked to the riboZyme 
coding sequences. The promoter that directs expression of the 
riboZyme may be any promoter functional in the host cell, 
prokaryotic promoters being desired in prokaryotic cells and 
eukaryotic promoters in eukaryotic cells. A promoter is com 
posed of discrete modules that direct the transcriptional acti 
vation and/ or repression of the promoter in the ho st cell. Such 
modules may be mixed and matched in the riboZyme’s pro 
moter so as to provide for the proper expression of the 
riboZyme in the host. A eukaryotic promoter may be any 
promoter functional in eukaryotic cells, and especially may 
be any of an RNA polymerase I, II or III speci?cally. If it is 
desired to express the riboZyme in a Wide variety of eukary 
otic host cells, a promoter functional in most eukaryotic host 
cells should be selected, such as a rRNA or a tRNA promoter, 
or the promoter for a Widely expressed mRNA such as the 
promoter for an actin gene, or a glycolytic gene. If it is desired 
to express the riboZyme only in a certain cell or tissue type, a 
cell-speci?c (or tissue-speci?c) promoter element that is 
functional only in that cell or tissue type should be selected. 
The trans-splicing reaction is chemically the same Whether 
it is performed in vitro or in vivo. HoWever, in vivo, the 
presence of the target and the riboZyme Will suf?ce to result in 
trans-splicing, since cofactors are usually already present in 
the host cell. 
It has been previously reported that, at high MgCl2 (10-100 
mM) and temperature (550 C. to 65° C.), Telrahymena group 
I intron riboZymes that lack both of the exons and the IGS can 
catalyZe a guanosine cofactor-mediated TES-like reaction 
upon binding pseudoknot structured substrates, Which creates 
the in trans equivalent of the P1 and P10 helices (P9.0 helix 
formation Was not required). The riboZymes target and bind 
these pseudoknot structures entirely through tertiary interac 
tions. In contrast, the riboZymes used in the present invention 
contain at least tWo modi?able REs. In a preferred embodi 
ment, the riboZyme contains modi?ed RBI and RE3. Which 
alloWs the riboZyme to target designated substrates at the 
level of simple base pairing. Furthermore, the TES reactions 
using the R carinii and Telrahymena riboZymes do not 
require a guanosine cofactor, and optimally occur at a loWer 
MgCl2 concentration (7-13 mM) and temperature (440 C.). 
Sullenger and Cech ((1994) Nature 371, 619-622.) previ 
ously reported that Telrahymena group I intron riboZymes 
that lack a 5' exon, but contain an endogenous non-native 3' 
exon, catalyZe the covalent attachment of the endogenous 3' 
exon to mutant transcripts in such a Way as to replace the 3' 
end of mutant transcripts With normal ‘corrected’ versions. 
While trans-splicing can repair RNA, it exploits only the RBI 
molecular interaction, the riboZymes must be covalently 
attached to the repaired half of the transcript, it is single 
turnover, and repairing mutations distant from the 3' end of 
long transcripts could be problematic. In contrast, the TES 
reaction exploits multiple molecular interactions (RE1, RE3, 
and perhaps RE2), TES riboZymes excise an internal segment 
from Within RNA substrates, the reaction is potentially mul 
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tiple turnover, and the position of the mutations Within the 
transcript is not a limiting factor. Moreover, that under the 
conditions used in this report, little (if any) turnover Was 
observed. 
Example 1 
0ligonucleotide synthesis and preparation. DNA oligo 
nucleotide primers Were purchased from Integrated DNA 
Technologies (Coralville, IoWa), and Were used Without fur 
ther puri?cation. RNA oligonucleotides Were purchased from 
Dharmacon Research Inc. (Boulder, Colo.) and deprotected 
folloWing the manufacturer’s protocol. The oligoribonucle 
otides Were 5' end radiolabeled and puri?ed via gel electro 
phoresis as previously described (Testa, S. M., Haidaris, C. 
G., Gigliotti, E, & Turner, D. H. (1997) Biochemistry 36, 
15303-15314.). The RNA products Were extracted from the 
gel slice by stirring for one hour With a sterile stir-bar in 1.5 
mL elution buffer containing 10 mM Tris (pH 7.4), 250 mM 
NaCl, and 1 mM EDTA. Gel particulate Was removed via 
centrifugation, and the solution Was evaporated to a ?nal 
oligoribonucleotide concentration of approximately 8 nM. 
Plasmid construction and synthesis. The R carinii 
riboZyme plasmid precursor, P-8/4x, Was generated as previ 
ously described (Testa, S. M., Haidaris, C. G., Gigliotti, E, & 
Turner, D. H. (1997) Biochemistry 36, 15303-15314). The 
Myotonic Dystrophy-speci?c riboZyme plasmid precursor, 
P-8/4x-MD, Was derived from the P-8/4x plasmid by site 
directed mutagenesis. Brie?y, three successive rounds of 
mutagenesis Were performed to modify each of the three 
recognition elements using the folloWing pairs of mutagenic 
primers (underlined bases represent altered recognition ele 
ments as compared to P-8/4x)1 5‘CACGCCGCTTTCE 
GAACCTCTATAGTGAGTCG3v (SEQ ID N011) and 5’CG 
ACTCACTATAGAGGTTCCCGAAAGCGGCGTG3v (SEQ 
ID N012) for RE1 formation, 5vGGTATAGTCTEC 
CTCTTTCGAAAG3v (SEQ ID N013) and 5vCTTTCGAAA 
GAGGC_AAGACTATACC3v for RE2 (SEQ ID N014) forma 
tion, and then 5vCGACTCACTATAQGTTCCCGAA 
AGCGGC3v (SEQ ID N015) and 5vGCCGCTTTCGGGAA 
C?TATAGTGAGTCG3v (SEQ ID N016) for RE3 forma 
tion. Each set of primers (15 pmol each primer) Was used in an 
ampli?cation reaction comprising 25 ng parental plasmid, 2.5 
units Pfu DNA polymerase (Stratagene; La Jolla, Calif.), and 
0.5 uM dNTPs in a buffer comprising 10 mM KCl, 10 mM 
(NH4)2S04, 20 mM Tris-HCl (pH 8.8), 2 mM MgS04, 0.1% 
Triton X-100, and 0.1 mg/mL BSA (?nal volume 50 uL). 
After an initial denaturation for 30 seconds at 95° C., the 
mixture Was subjected to 15 cycles of 95° C. for 30 seconds, 
500 C. for tWo minutes, and 68° C. for six minutes. Parental 
plasmid Was then digested With 20 units Dpn I (Gibco BRL; 
Rockville, Md.) in 5.7 pL of the manufacturer’s supplied 
buffer for 2 hours at 37° C. 3 pL of this mixture Was then used 
to transform E. coli DHSO. competent cells (Gibco BRL). The 
vectors Were puri?ed using a QIAprep Spin Miniprep Kit 
(QIAGEN; Valencia, Calif.). The resultant ?nal plasmid, P-8/ 
4x-MD, Was sequenced for con?rmation (ACGT, Inc; North 
brook, Ill.). The plasmids Were lineariZed With Xba I, phenol/ 
chloroform extracted, and ethanol precipitated in preparation 
for run-off transcription. 
Transcription. Both rP-8/4x and rP-8/4x-MD Were tran 
scribed from their appropriate plasmid precursors essentially 
as previously described for rP-8/ 4x (Testa, S. M., Haidaris, C. 
G., Gigliotti, E, & Turner, D. H. (1997) Biochemistry 36, 
15303-15314). A typical transcription reaction (40 pL) con 
tained 1 ug lineariZed plasmid, 40 mM Tris-HCl (pH 7.4), 5 
mM dithiothreitol, 5 mM spermidine, 5 mM MgCl2, 1.5 mM 
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each NTP, 1.25 mg/mL BSA, and 4 pL of T7 RNA poly 
merase (100 units/uL) and Was incubated for tWo hours at 37° 
C. The resultant RNA Was puri?ed using QIAGEN-tip 100 
anion-exchange columns. First, each column Was equili 
brated With 4.0 mL of Buffer I (750 mM NaCl, 50 mM MOPS 
(pH 7.0), 15% ethanol, and 0.15% Triton X-100). Second, the 
transcription reactions Were loaded onto the column and the 
column Was Washed With 7.0 mL of Buffer I. Third, the 
transcripts Were eluted using 4.0 mL of Buffer II (1.0 M NaCl, 
50 mM MOPS (pH 7.0), and 15% ethanol). FolloWing an 
isopropanol and then an ethanol precipitation, the samples 
Were dissolved in Water and quanti?ed using a Beckman 
UV-VIS DU-650 spectrophotometer. 
Trans-excision-splicing reactions. Reactions Were con 
ducted in H><Mg buffer consisting of 50 mM Hepes (25 mM 
Na”), 135 mM KCl, and x mM MgCl2 (listed in the ?gures) at 
pH 7.5. The trans-excision-splicing reactions Were optimiZed 
for the rP-8/4x and rP-8/4x-MD riboZymes over a MgCl2 
concentration range of0 to 50 mM at 30° C., 37° C., and 44° 
C. Maximum product formation occurred at 44° C. for both 
riboZymes, 7 mM MgCl2 for rP-8/4x, and 13 mM MgCl2 for 
rP-8/4x-MD, although a signi?cant amount of each product 
Was obtained at 37° C. at both 7 and 13 mM MgCl2 for each 
riboZyme (data not shoWn). Prior to each reaction, 1.0 pmol of 
riboZyme in 5.0 pL of the appropriate buffer Was preannealed 
at 60° C. for ?ve minutes and then alloWed to sloW-cool to the 
appropriate temperature. Reactions using the rP-8/ 4x 
riboZyme Were initiated by adding 1.0 pL of 8 nM radiola 
beled 36-mer, 12-mer, or 10-merR carinii-speci?c substrates 
or the 38-mer Myotonic Dystrophy substrate. Reactions 
using the rP-8/4x-MD riboZyme Were initiated by adding 1.0 
uL of 8 nM radiolabeled 38-mer Myotonic Dystrophy-spe 
ci?c substrate or the 36-merR carinii substrate. The substrate 
sequences and hoW they base pair With the riboZymes are 
shoWn in FIG. 2. In each case the substrates Were preincu 
bated in the appropriate buffer (listed in the ?gures). After one 
hour, the reactions Were terminated by adding an equal vol 
ume of stop buffer (10 M urea, 3 mM EDTA, and 0.1><TBE). 
The products and reactants Were denatured for one minute at 
90° C. and then separated on a 12% acrylamide/ 8 M urea gel. 
The gel Was transferred to chromatography paper (Whatman 
3MM CHR) and dried under vacuum. The bands Were visu 
aliZed and quanti?ed on a Molecular Dynamics Storm 860 
Phosphorimager. 
The observed rate constant, kobs, for the ?rst (5' cleavage) 
and second (exon ligation) step of each reaction Was quanti 
?ed (Testa, S. M., GryaZnov, S. M. & Turner, D. H. (1998) 
Biochemistry 37, 9379-9385; Mahadevan, M., Tsil?dis, C., 
Sabourin, L., Shutler, G., Amemiya, C., Jansen, G., Neville, 
C., Narang, M., Barcelo, 1., 0’Hoy, K., et al (1992) Science 
255, 1253-1255). The ?rst step Was obtained from a plot of 
the percent intermediate plus percent product formed versus 
time, and the second step Was obtained from a plot of percent 
product formed versus time. These observed rate constants 
re?ect the rate of chemistry and any requisite conformation 
changes that occur. 
Sequencing the trans-excision-splicing products. Products 
obtained from the trans-excision-splicing reactions Were gel 
puri?ed and sequenced by partial nuclease digestion using T1 
(Epicentre; Madison, Wis.), U2 (Research Unlimited; Well 
ington, NeW Zealand), and Cl-3 (Research Unlimited) RNA 
nucleases. T1 reactions used 1.0><1 units T1 in 200 mM Tris 
HCl (pH 7.5), Cl-3 reactions used 0.33 units Cl-3 in 200 mM 
Tris-HCl (pH 7.5), and U2 reactions used 0.33 units U2 in 200 
mM Tris-HCl (pH 3.5). Sequencing reactions utiliZed 
approximately 50 fmol of RNA and Were incubated for 10 
minutes at 55° C. Immediately after adding an equal volume 
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of stop buffer to each reaction, aliquots Were loaded on a 
13.5% polyacrylamide/8 M urea gel. In parallel With the 
above reactions, We enZymatically sequenced chemically 
synthesized versions of the expected trans-excision-splicing 
products for comparison. 
To determine if the 3' product of the ?rst reaction step (5' 
cleavage) (FIG. 1B) is dissociating and then rebinding the 
same (or different) riboZyme before the second reaction step 
(exon ligation), TES reactions Were conducted for one hour in 
7 mM MgCl2, 166 nM rP-8/4x riboZyme, 1.33 nM radiola 
beled 36-mer substrate, and either 66.5 nM (50x) or 665 nM 
(500x) 3' exon mimic competitor r(GUGCUCU) (SEQ ID 
NO: 16). The values reported are the average of six indepen 
dent assays. Likewise, to determine if the 5' product of the 
?rst reaction step (5' cleavage) (FIG. 1B) is dissociating and 
then rebinding the riboZyme before the second step (exon 
ligation), TES reactions Were conducted for one hr in 7 mM 
MgCl2, 166 nM rP-8/4x riboZyme, 1.33 nM 36-mer non 
radiolabeled substrate, and 1.33 nM radiolabeled 5' exon 
mimic competitor r(AUGACU) (SEQ ID NO:15). In each 
case the competitors Were added simultaneously With the 
substrates. 
Example 2 
The R carinii group I intron riboZyme catalyZes the trans 
excision- splicing reaction In order to test Whether a riboZyme 
derived from a group I intron, and speci?cally one from R 
carinii, catalyZes the trans-excision-splicing reaction, a sub 
strate Was designed that Would bind the rP-8/4x riboZyme’s 
native recognition element sequences (RE1, RE2, and RE3 in 
FIG. 1b). These substrate sequences Were connected With a 
bridge consisting of the ?rst four bases of the intron and 13 
uridines (FIG. 2A). Uridines Where chosen because of their 
relatively poor ability to form self-structures and the number 
of uridines (13) Was chosen arbitrarily. Typical results at the 
optimiZed MgCl2 concentration (7 mM) and the temperature 
(440 C.) are shoWn in FIG. 3A. 
The expected product band at 16 nucleotides in length Was 
obtained in a yield of 25%:5% (for 6 independently run 
assays). This band Was extracted from the gel matrix, repuri 
?ed, and subjected to enZymatic sequencing, along With a 
chemically synthesiZed version of the expected product. The 
sequence and banding patterns Were identical (FIG. 4), indi 
cating that the expected trans-excision-splicing product Was 
generating. The reaction also produced a band at six nucle 
otides. This is a product of the ?rst step of the tWo-step 
trans-excision-splicing reaction (5' cleavage), and indicates 
that a portion of the transcript undergoes only the ?rst step of 
the reaction. Also produced is a small amount of riboZyme 
mediated 3' splice site hydrolysis product at 26 nucleotides. 
Nonetheless, the rP-8/ 4x riboZyme contains the ability to bind 
a substrate in trans and catalyZe the excision-splicing reac 
tion. 
Apparently, a majority of the 36-mer substrate undergoes 
only the ?rst step of the reaction. The dependence of the TES 
reaction on MgCl2 concentration, time, and rP-8/4x concen 
tration is shoWn in FIG. 3B. The kobs for the ?rst and second 
step of the reaction are 1.69 and 0.05 min_l, respectively. The 
reaction is complete after 40 minutes and only requires 20 nM 
riboZyme for maximal activity (With 1.33 nM substrate). 
These results shoW that the rP-8/ 4x riboZyme, in the absence 
of a nucleotide cofactor, inherently contains the ability to bind 
a substrate in trans and catalyZe the TES reaction. 
Even though there are 18 other uridines that could be sites 
of 5' cleavage and four other guanosines that could be sites of 
3' splicing for the 36-mer substrate, only the expected TES 
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product is generated. Apparently, the riboZyme recognition 
elements that de?ne the individual catalytic steps are 
sequence speci?c. That the riboZyme can catalyZe this reac 
tion at all is surprising in that the relatively long bridging 
region could be expected to sterically hinder the binding of 
the substrate to the catalytic core of the riboZyme, or at least 
signi?cantly hinder the required conformational rearrange 
ment betWeen the tWo catalytic steps. One or both of these 
might account for the majority (>50%) of the 36-mer sub 
strate only undergoing the ?rst catalytic step, in contrast to 
less than 10% only undergoing the ?rst step for the self 
splicing reaction in vitro (15, 17). The lack of product break 
doWn seen in the time dependence studies, hoWever, indicates 
that the TES products themselves are not substrates for fur 
ther reactions, although guanosine dependent 5' cleavage or 
riboZyme-mediated hydrolysis of the products could be a 
factor in vivo. 
Previous studies utiliZing the rP-8/4x riboZyme (Testa, S. 
M., GryaZnov, S. M. & Turner, D. H. (1998) Biochemistry 37, 
9379-9385) shoW that the 5' exon mimic r(AUGACU) (SEQ 
ID NO:15) binds to the rP-8/4x riboZyme (Kd:5.2 nM at 37° 
C.) three orders of magnitude more tightly than the 3' exon 
mimic r(GUGCUCU) (SEQ ID NO:16) (Kdz20 uM at 37° 
C.). Interestingly, maximum TES product formation occurs 
With as little as 20 nM riboZyme (at 44° C.), indicating that for 
?nal product formation the 5' and 3' exon intermediates pro 
duced during the 5' cleavage step might not dissociate and 
then rebind the riboZyme before the exon ligation step. To test 
for 5' exon dissociation and rebinding betWeen the tWo steps, 
TES reactions Were conducted With 166 nM rP-8/4x, 1.33 nM 
non-radiolabelled 36-mer, and 1.33 nM radiolabeled 5' exon, 
r(AUGACU) (SEQ ID NO:15). In this case, if the 5' exon 
intermediate dissociates from the riboZyme, the radiolabeled 
5' exon is just as likely to then bind the riboZyme and form the 
16-mer product as the non-radiolabeled 5' exon intermediate. 
As seen in FIG. 5, no radiolabeled TES products are observed, 
indicating the 5' exon intermediate does not dissociate from 
the riboZyme betWeen the tWo steps (for those 5' exon inter 
mediates that undergo the complete reaction). 
Likewise, to test for 3' exon intermediate dissociation and 
rebinding betWeen the tWo reaction steps, TES reactions Were 
conducted With 166 nM rP-8/4x, 1.33 nM radiolabeled 
36-mer, and a 50 (66.5 nM) or 500 (665 nM) fold excess ofa 
non-radiolabeled 3' exon mimic competitor, r(GUGCUCU) 
(SEQ ID NO: 16), Which Would form a 10-mer competition 
product. At equal molar concentrations if the 3' exon inter 
mediate dissociates from the riboZyme, the 7-mer competitor 
is 2.5 times more likely to bind the riboZyme and be a sub 
strate in the second reaction step than the 30-mer 3' exon 
intermediate (data not shoWn). The results (FIG. 5) shoW that 
a 500-fold excess of cold competitor over substrate does not 
signi?cantly reduce the amount of 16-mer product formed 
(19.4%:2.3% versus 22.8%:3%, respectively). The small 
amount of 10-mer product that is observed at 500-fold excess 
competitor over substrate (but not 50-fold excess) is not actu 
ally competing With the TES reaction. In these cases, the 
riboZymes that have bound radiolabeled 5' exon regions, and 
for Which the 3' exon region has dissociated, are binding and 
reacting With a small amount of the huge excess of 3' exon 
competitor. Therefore, the vast majority of substrates that 
undergo the complete TES reaction do not have 3' exon inter 
mediate dissociation and rebinding occurring betWeen the 
tWo steps of the reaction. Apparently, substrates that undergo 
only the ?rst reaction step do so because of nearly irreversible 
5' or 3' exon intermediate dissociation. It folloWs that since 
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intermediates to the complete TES reaction do not dissociate 
from the riboZyme, the TES reaction is intramolecular With 
regard to substrate. 
Example 3 
Excision of a single nucleotide using the R carinii. 
riboZyme. In order to determine if a loWer limit exists to the 
length of the excised region, We tested the TES reaction using 
the rP-8/ 4x riboZyme With tWo neW substrates. One substrate 
is a 12-mer, r1 AUGACUGUGCUC) (SEQ ID NO: 7), and 
Was designed to contain the minimum length bridging 
sequence that could utiliZe the 2 base pair RE2 interaction (to 
form the P90 helix) and the 3' guanosine thought to be 
required for self-splicing (FIG. 2Bi). The other substrate is a 
10-mer, r1 AUGACUGE) (SEQ ID NO: 8), Which can not 
utiliZe the RE2 interaction, and from Which only one nucle 
otide Would be excised (FIG. 2B ii). The results (FIG. 3A) 
shoW that, under the optimal conditions of 10 mM MgCl2 and 
440 C., both the 12-mer and 10-mer reactions lead to the 
formation of the expected 9-mer products, as con?rmed by 
enzymatic sequencing (data not shoWn). The optimiZed reac 
tions produce 72%:3.9% product for the 12-mer substrate 
and 69.3%:4.4% product for the 10-mer substrate (for 6 
independently run assays). Thus, the rP-8/4x riboZyme can 
excise as little as a single nucleotide. The same approximate 
yield is obtained using the 12-mer and 10-mer substrates 
Which suggests that the role of forming the P90 helix is not 
large in this case. Therefore, the RE2 interaction, although 
perhaps bene?cial, is not required for sequence speci?c TES 
reactions. In addition, the 12-mer and 10-mer substrates lead 
to more than tWice the product as compared With the 36-mer 
substrate, implicating the longer bridging region (Which 
includes the four 5' bases of the intron) as being detrimental 
for this reaction. As the amount of substrate that undergoes at 
least the ?rst reaction step is similar for all of the different 
substrates, 3' exon intermediate dissociation for the 36-mer 
likely accounts for the difference in extent of ?nal product 
formation. The dependence of the 10-mer substrate reaction 
on MgCl2 concentration, time, and rP-8/4x concentration is 
shoWn in FIG. 3C. The kobs for the ?rst and second step of the 
reaction are 4.12 and 2.89 min-l, respectively. In contrast to 
that for the 36-mer, the reaction With the 10-mer substrate is 
more favorable at MgCl2 concentrations greater than 7 mM, 
and the second reaction step occurs approximately 50-fold 
faster. The origin of this effect is unknown, but could be due 
to the reduced steric hindrance of the smaller bridge on the 
required conformational rearrangement betWeen the tWo 
reaction steps. This could re?ect an increased a?inity or 
accessibility of the 3' guanosine of the bridge for the G-bind 
ing site of the riboZyme. Indeed, previous reports suggest that 
the ability of the G-binding site to bind this endogenous 
guano sine drives the second step of the reaction (Mahadevan, 
M., Tsil?dis, C., Sabourin, L., Shutler, G., Amemiya, C., 
Jansen, G., Neville, C., Narang, M., Barcelo, 1., O’Hoy, K., et 
al (1992) Science 255, 1253-1255; Harley, H. G., Rundle, S. 
A., MacMillan, 1. C., Myring, 1., Brook, 1. D., CroW, S., 
Reardon, W., Fenton, I., ShaW, D. 1., & Harper, P. S. (1993) 
Am. .1. Hum. Genet. 52, 1164-1174). 
Example 4 
The sequence speci?city of the P carinii riboZyme can be 
altered. For the TES reaction to be useful, the recognition 
elements must be mutable in order to target predetermined 
sequences. Therefore, a truncated DMPK mimic model sys 
tem Was developed (FIG. 2Biii) for analyZing the ability of a 
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re-engineered riboZyme to excise the RNA triplet repeat 
region Whose expansion is the causative agent of the effects of 
the genetic disease, Myotonic Dystrophy. A riboZyme Was 
designed to target the uridine immediately upstream of the 
repeats. Because there are ?ve successive guanosines imme 
diately folloWing the repeats (Which could lead to a mixture of 
TES products), the ?rst guanosine doWnstream from the ?ve 
successive guanosines Was targeted. The substrate bridge 
contained 5 CUG repeats, as this is the smallest number of 
repeats thought to form the hairpin structure similar to that 
seen With the expanded transcripts. Myotonic Dystrophy 
patients actually have greater than 15 CUG repeats. Never 
theless, the riboZyme targets the ?anking regions and Would 
be the same regardless of the number of triplet repeats. This 
riboZyme is referred to as the rP-8/4x-MD riboZyme and this 
substrate the 38-mer DMPK mimic. The results at the opti 
mum MgCl2 concentration (13 mM) and temperature (440 C.) 
are shoWn in FIG. 6A. A 10 nucleotide product Was obtained, 
as expected, in a yield of 61 .1%:4.6% (for 6 independently 
run assays). Besides unreacted 6-mer generated from the ?rst 
step of the reaction, no other products are produced to any 
signi?cant amount, indicating a reasonably speci?c reaction. 
The 10-mer product Was extracted from the gel and enZymati 
cally sequenced, along With a chemically synthesiZed version 
of the expected product. The sequence and banding patterns 
obtained (FIG. 4) shoW that the expected TES product is 
being generated. Apparently, the riboZyme can be modi?ed 
(at RE1, RE2, and RE3) to target non-native substrates. The 
dependence of this reaction on MgCl2 concentration, time, 
and rP-8/4x-MD concentration is shoWn in FIG. 6B. The kobs 
for the ?rst and second step of the reaction are 0.41 and 0.44 
min_l, respectively (note that these values are Within experi 
mental error and the rate of the second step is likely limited by 
the rate of the ?rst step). Interestingly, the excision of this 
28-mer bridge, Which could include a triplet repeat hairpin 
structure, is substantially more effective than the 36-mer rP-8/ 
4x system, Which excises a 20-mer unstructured bridge. Thus, 
targets With large bridge regions are not necessarily poor 
reaction substrates. 
To determine Whether each riboZyme has speci?city for its 
intended target, TES reactions Were run using the rP-8/4x 
MD riboZyme With the 36-mer P carinii substrate at 13 mM 
MgCl2, and the rP-8/4x riboZyme With the 38-mer DMPK 
mimic at 7 mM MgCl2, each at 440 C. (FIG. 6A). In addition, 
the reaction Was run using the rP-8/4x-MD riboZyme at 7 mM 
MgCl2 and another reaction using the rP-8/ 4x riboZyme Was 
run at 13 mM MgCl2 (data not shoWn). In these reactions, not 
even 5' cleavage products are observed, indicating that the 
riboZymes have some speci?city for their intended target 
substrates. Although the MgCl2 concentration required for 
maximum activity differs for all the reactions, they all occur 
at or beloW that required (15 mM) for maximum activity for 
the R carinii group I intron self-splicing reaction in vitro. 
While it Was knoWn that the sequence of RE1 could be modi 
?ed in reactions mimicking the ?rst step of the self-splicing 
reaction (14, 20, 21), it Was previously not knoWn that all 
three recognition elements are modi?able. That these recog 
nition elements completely specify binding and reactivity 
indicates that they are the primary determinants of speci?city 
betWeen the riboZyme and its substrate. In addition, bridging 
regions of different sequences and lengths (1, 3, 20, and 28 
nucleotides) have been excised, indicating that perhaps a 3' G 
in the bridging region might be the only sequence require 
ment for the excised segment. 
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SEQUENCE LISTING 
<l60> NUMBER OF SEQ ID NOS: 21 
<2ll> LENGTH: 33 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<220> FEATURE: 
<22l> NAME/KEY: miscifeature 
<222> LOCATION: (13) . . (l8) 
<223> OTHER INFORMATION: Represent altered recognition elements as 
compared to P-8/4X 
<400> SEQUENCE: l 
cacgccgctt tcgggaacct ctatagtgag tcg 33 
<2ll> LENGTH: 33 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<220> FEATURE: 
<22l> NAME/KEY: miscifeature 
<222> LOCATION: (15) . . (21) 
<223> OTHER INFORMATION: Represent altered recognition elements as 
compared to P-8/4X 
<400> SEQUENCE: 2 
cgactcacta tagaggttcc cgaaagcggc gtg 33 
<2ll> LENGTH: 25 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<220> FEATURE: 
<22l> NAME/KEY: miscifeature 
<222> LOCATION: (11) . . (l2) 
<223> OTHER INFORMATION: Represent altered recognition elements as 
compared to P-8/4X 
<400> SEQUENCE: 3 
ggtatagtct tgcctctttc gaaag 25 
<2ll> LENGTH: 25 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<220> FEATURE: 
<22l> NAME/KEY: miscifeature 
<222> LOCATION: (14) . . (l5) 
<223> OTHER INFORMATION: Represent altered recognition elements as 
compared to P-8/4X 
<400> SEQUENCE: 4 
ctttcgaaag aggcaagact atacc 25 
<2ll> LENGTH: 30 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
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—cont inued 
<220> FEATURE: 
<22l> NAME/KEY: miscifeature 
<222> LOCATION: (13) . . (l5) 
<223> OTHER INFORMATION: Represent altered recognition elements as 
compared to P-8/4X 
<400> SEQUENCE: 5 
cgactcacta taggtgttcc cgaaagcggc 3O 
<2ll> LENGTH: 30 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<220> FEATURE: 
<22l> NAME/KEY: miscifeature 
<222> LOCATION: (16) . . (l8) 
<223> OTHER INFORMATION: Represent altered recognition elements as 
compared to P-8/4X 
<400> SEQUENCE: 6 
gccgctttcg ggaacaccta tagtgagtcg 3O 
<2ll> LENGTH: 12 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: 7 
augacugugc uc l2 
<2ll> LENGTH: 10 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: 8 
augacugcuc l0 
<2lO> SEQ ID NO 9 
<2ll> LENGTH: 332 
<2l3> ORGANISM: Pneumocystis carinii 
<400> SEQUENCE: 9 
gagggucaug aaagcggcgu gaaaacguua gcuagugauc uggaauaaau ucagauugcg 6O 
acacugucaa auugcgggga agcccuaaag auucaacuac uaagcaguuu guggaaacac 120 
agcuguggcc gaguuaauag cccuggguau aguaacaaug uugaauauga aucuuuugcg 180 
agaugaaaug ggugauccgc agccaagucc uaagggcauu uuugucuaug gaugcaguuc 240 
aacgacuaga uggcaguggg uauuguaagg aauugcaguu uucuugcagu gcuuaaggua 300 
uagucuaucc ucuuucgaaa gaaagaguau au 332 
<2lO> SEQ ID NO 10 
<2ll> LENGTH: 36 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
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22 
augacu 
gagggu 
gggaau 
augacu 
augacu 
gugcuc 
SEQUENCE: lO 
cacc uuuuuuuuuu uuugugcucu uaaggu 
SEQ ID NO 11 
LENGTH: 11 
TYPE: RNA 
ORGANISM: Pneumocystis carinii 
SEQUENCE: ll 
caua L1 
SEQ ID NO 12 
LENGTH: 38 
TYPE: RNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Chemically synthesized 
SEQUENCE: l2 
gcug cugcugcugc uggggggauc acagacca 
SEQ ID NO 13 
LENGTH: 11 
TYPE: RNA 
ORGANISM: Pneumocystis carinii 
SEQUENCE: l3 
cccu g 
SEQ ID NO 14 
LENGTH: 16 
TYPE: RNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Chemically synthesized 
SEQUENCE: l4 
cucu uaaggu 
SEQ ID NO 15 
LENGTH: 6 
TYPE: RNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Chemically synthesized 
SEQUENCE: l5 
SEQ ID NO 16 
LENGTH: '7 
TYPE: RNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Chemically synthesized 
SEQUENCE: 16 
SEQ ID NO 17 
LENGTH: 10 
TYPE: RNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Chemically synthesized 
36 
ll 
38 
ll 
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